Gene Logic will work with H. Lundbeck to reposition some of the latter’s drug candidates. These compounds were discontinued or de-prioritized in clinical trials for reasons other than safety, according to the companies.
The drug repositioning agreement provides for milestones and royalties similar to those paid for development-stage in-licensing deals, discounted to account for Lundbeck's contribution as the originator of the compound. Gene Logic retains the option to exclusively license any candidate for which Gene Logic identifies a potential new use and Lundbeck chooses not to pursue. In such a case Lundbeck will be payed success-based milestones and royalties.